Plain-English translation of NCT06592352 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing modafinil, a medication already approved to treat excessive sleepiness, to see if it can help improve thinking and memory problems that many people with multiple sclerosis experience. Earlier studies suggest this medication may help with memory, focus, and problem-solving, but it doesn't work equally well for everyone. This trial will help doctors figure out which patients are most likely to benefit from the treatment.
Currently, there are no approved medications specifically designed to treat thinking and memory problems in people with multiple sclerosis, even though these problems significantly affect daily life. This trial aims to better understand how this medication works in the brain and identify which patients are most likely to respond well to it.
You likely qualify if…
You likely don't qualify if…
You would take a daily dose of 200 mg of the medication by mouth for 3 months while being monitored at a neurology clinic in Braga, Portugal. During the trial, you'll complete memory and thinking tests (including a test called the Symbol Digit Modalities Test) and have brain imaging scans (fMRI) before and after treatment to show how the medication affects your brain activity. After you stop taking the medication, you'll continue in a safety follow-up phase for another 3 months.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Portugal